258 related articles for article (PubMed ID: 25708258)
41. Open label study to assess infliximab safety and timing of onset of clinical benefit among patients with rheumatoid arthritis.
Shergy WJ; Isern RA; Cooley DA; Harshbarger JL; Huffstutter JE; Hughes GM; Spencer-Smith EA; Goldman AL; Roth SH; Toder JS; Warner D; Quinn A; Keenan GF; Schaible TF;
J Rheumatol; 2002 Apr; 29(4):667-77. PubMed ID: 11950005
[TBL] [Abstract][Full Text] [Related]
42. Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease.
Steenholdt C; Svenson M; Bendtzen K; Thomsen OØ; Brynskov J; Ainsworth MA
Aliment Pharmacol Ther; 2011 Jul; 34(1):51-8. PubMed ID: 21535447
[TBL] [Abstract][Full Text] [Related]
43. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.
Baert F; Noman M; Vermeire S; Van Assche G; D' Haens G; Carbonez A; Rutgeerts P
N Engl J Med; 2003 Feb; 348(7):601-8. PubMed ID: 12584368
[TBL] [Abstract][Full Text] [Related]
44. A Quality Improvement Approach to External Infliximab Infusions in Pediatric Inflammatory Bowel Disease.
Gupta SR; Crandall WV; Donegan A; Johnson M; Drobnic B; Oates M; Boyle B; Maltz RM; Dotson JL
J Pediatr Gastroenterol Nutr; 2019 Nov; 69(5):544-550. PubMed ID: 31219936
[TBL] [Abstract][Full Text] [Related]
45. Impact of persistence with infliximab on hospitalizations in ulcerative colitis.
Carter CT; Leher H; Smith P; Smith DB; Waters HC
Am J Manag Care; 2011 Jun; 17(6):385-92. PubMed ID: 21756009
[TBL] [Abstract][Full Text] [Related]
46. The safety of infliximab infusions in the community setting.
Ducharme J; Pelletier C; Zacharias R
Can J Gastroenterol; 2010 May; 24(5):307-11. PubMed ID: 20485705
[TBL] [Abstract][Full Text] [Related]
47. Tolerability of shortened infliximab infusion times in patients with inflammatory bowel diseases: a single-center cohort study.
Breynaert C; Ferrante M; Fidder H; Van Steen K; Noman M; Ballet V; Vermeire S; Rutgeerts P; Van Assche G
Am J Gastroenterol; 2011 Apr; 106(4):778-85. PubMed ID: 21407184
[TBL] [Abstract][Full Text] [Related]
48. Infliximab for very early-onset inflammatory bowel disease: A tertiary center experience in Japan.
Takeuchi I; Kaburaki Y; Arai K; Shimizu H; Hirano Y; Nagata S; Shimizu T
J Gastroenterol Hepatol; 2020 Apr; 35(4):593-600. PubMed ID: 31425641
[TBL] [Abstract][Full Text] [Related]
49. Infliximab as a rescue therapy for hospitalized patients with severe ulcerative colitis refractory to systemic corticosteroids.
Yamamoto-Furusho JK; Uzcanga LF
Dig Surg; 2008; 25(5):383-6. PubMed ID: 19005257
[TBL] [Abstract][Full Text] [Related]
50. Nurse-led outpatient clinics in oncology care - Patient satisfaction, information and continuity of care.
Berglund CB; Gustafsson E; Johansson H; Bergenmar M
Eur J Oncol Nurs; 2015 Dec; 19(6):724-30. PubMed ID: 26071199
[TBL] [Abstract][Full Text] [Related]
51. Infliximab drug and infusion costs among patients with Crohn's disease in a commercially-insured setting.
Ollendorf DA; Lidsky L
Am J Ther; 2006; 13(6):502-6. PubMed ID: 17122530
[TBL] [Abstract][Full Text] [Related]
52. Successful induction of tolerance to infliximab in patients with Crohn's disease and prior severe infusion reactions.
Duburque C; Lelong J; Iacob R; Seddik M; Desreumaux P; Fournier C; Wallaert B; Cortot A; Colombel JF
Aliment Pharmacol Ther; 2006 Sep; 24(5):851-8. PubMed ID: 16918890
[TBL] [Abstract][Full Text] [Related]
53. Safety and effectiveness of infliximab for inflammatory bowel diseases in clinical practice.
Tursi A; Elisei W; Brandimarte G; Giorgetti G; Penna A; Castrignano V
Eur Rev Med Pharmacol Sci; 2010 Jan; 14(1):47-55. PubMed ID: 20184089
[TBL] [Abstract][Full Text] [Related]
54. Prevention of infusion reactions to infliximab in paediatric patients with oral acetylsalicylic acid.
Hämäläinen A; Lahdenne P; Wikström A; Aalto K; Kolho KL
Clin Exp Rheumatol; 2012; 30(4):590-1. PubMed ID: 22766212
[No Abstract] [Full Text] [Related]
55. [PREMEDICATION WITH CORTICOSTEROIDS PRIOR TO IV INFLIXIMAB - A COMPARISON BETWEEN INFLAMMATORY BOWEL DISEASE (IBD) AND RHEUMATIC PATIENTS].
Oshri D; Schwarz D; Vodonos A; Zimhony N; Abu-Shakra M; Zeller L
Harefuah; 2019 Sep; 158(9):571-575. PubMed ID: 31507106
[TBL] [Abstract][Full Text] [Related]
56. Safety of infliximab in children with IBD: the experience of an academic center in WV.
Northcutt M; Al-Subu A; Bella B; Elitsur Y
W V Med J; 2014; 110(3):26-9. PubMed ID: 24984403
[TBL] [Abstract][Full Text] [Related]
57. Dual therapy with infliximab and immunomodulator reduces one-year rates of hospitalization and surgery among veterans with inflammatory bowel disease.
Abraham NS; Richardson P; Castillo D; Kane SV
Clin Gastroenterol Hepatol; 2013 Oct; 11(10):1281-7. PubMed ID: 23792295
[TBL] [Abstract][Full Text] [Related]
58. Adverse reactions to infliximab and the outcome of desensitization.
Mourad AA; Boktor MN; Yilmaz-Demirdag Y; Bahna SL
Ann Allergy Asthma Immunol; 2015 Aug; 115(2):143-6. PubMed ID: 26093777
[TBL] [Abstract][Full Text] [Related]
59. The effects of infliximab maintenance therapy on health-related quality of life.
Feagan BG; Yan S; Bala M; Bao W; Lichtenstein GR
Am J Gastroenterol; 2003 Oct; 98(10):2232-8. PubMed ID: 14572573
[TBL] [Abstract][Full Text] [Related]
60. The long-term outcome of anti-tumor necrosis factor-α therapy related to fecal calprotectin values during induction therapy in pediatric inflammatory bowel disease.
Kolho KL; Sipponen T
Scand J Gastroenterol; 2014 Apr; 49(4):434-41. PubMed ID: 24597837
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
